Abstract
BackgroundCurrent treatments for psoriatic arthritis (PsA) are associated with a range of limitations, e.g. side effects, safety concerns and inadequate efficacy. The economic burden of biologic (b)DMARD failure among patients...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have